by Alan McCann | Sep 14, 2020 | Uncategorized
European approval for novel device supporting surgical treatment of lymphedema September 14, 2020 (Union City, CA) – Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced that it has received CE mark for its first...
by Alan McCann | Jun 3, 2020 | Uncategorized
Exclusive agreement for Terumo to market and distribute Fibralign’s BioBridge in Japan June 02, 2020 06:00 AM Eastern Daylight Time UNION CITY, Calif.–(BUSINESS WIRE)–Fibralign Corp., a Stanford spin-out developer of therapeutic biomedical devices, has...
by fibralign | Jan 22, 2019 | Uncategorized
Fibralign announced today that it has been awarded a Small Business Innovation Research (SBIR) Sequential Phase II (Phase IIS) from the Department of Defense (DoD) Defense Health Program (DHP). This two-year grant provides $996,609 in funding to continue advancing...
by Alan McCann | Jan 12, 2019 | Uncategorized
Fibralign received Certification Notification on January 21, 2019 from DEKRA Certification B. V. that the Company’s management system meets the requirements of EN ISO 13486:2016. This internationally agreed standard sets out the requirements for a quality...
by fibralign | Feb 17, 2018 | Uncategorized
Fibralign received Certification Notification on February 18, 2018 from notifying body DEKRA Certification B. V. that it’s management system meets the requirements of EN ISO 13486:2016:2012 + AC:2012. The scope of the certification is for the design,...
by Alan McCann | Jun 22, 2016 | Uncategorized
Researchers at the School of Medicine have developed a possible treatment for lymphedema, the severe swelling of an arm or leg that can occur when the lymph system is blocked. Using scaffolding composed of specially patterned collagen nanofibers, the researchers...
